Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

NCT02362997 on ClinicalTrials.gov Phase 2 Dana-Farber Cancer Institute (academic or other) Started 2015-04-30 Completed

Riskier than 97% of active trials

Model scores of the 29,894 trials active now.

Model score 31% for any early termination, 18% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2023-06-30, after 2015-04-30 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celleligiblelongvaccinechemotherapy
Phrases that lowered it: relapsedparticipants withrefractoryasctparticipant
Sponsor's past termination rate: 15.0% (raises risk) · Sponsor's track record
Accepts healthy volunteers: No (raises risk) · Who can join
Phase: 2 (raises risk) · Design
Disease area, cancer: Yes (raises risk) · Disease area
Has a data monitoring committee: Yes (raises risk) · Design
Trials the sponsor started in the prior 2 years: 59 (lowers risk) · Sponsor's track record
Sponsor type: academic or other (raises risk) · Sponsor's track record
Sponsor's past trials: 207 (lowers risk) · Sponsor's track record
Design: parallel (raises risk) · Design
Minimum age: 18 (raises risk) · Who can join
Primary purpose: treatment (raises risk) · Design
Number of arms: 3 (lowers risk) · Design
Blinding: none (raises risk) · Design
Drug's FAERS reports marked serious: 74.8% (lowers risk) · Drug's FDA history
Collaborators: 1 (raises risk) · Design
Responsible party: principal investigator (lowers risk) · Design
Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 2
Number of arms: 3 (typical: 2)
Allocation: non randomized (typical: randomized)
Design: parallel
Primary purpose: treatment
Blinding: none
Has a data monitoring committee: Yes (typical: 56% yes)
Responsible party: principal investigator (typical: sponsor)
Collaborators: 1 (typical: 0)
Keywords listed: 3 (typical: 1)

Who can join

Minimum age: 18
Maximum age: not given (typical: 71)
Sex: all
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: academic or other
Sponsor's past trials: 207 (typical: 32)
Sponsor's past termination rate: 15.0% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 59 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 870 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 868 (typical: 412.5)
Drug's FAERS reports marked serious: 74.8% (typical: 85.6%)
Drug's FAERS reports with a death: 21.3% (typical: 15.9%)

Disease area and drugs

Disease areas: cancer, immunology, hematology
Drugs matched to FDA substances: pembrolizumab

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) NCT03990961 · started 2019 · scored riskier than 76% of active trials terminated
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) NCT04875195 · started 2021 · scored riskier than 77% of active trials completed
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk NCT03436862 · started 2018 · scored riskier than 98% of active trials completed
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) NCT03870945 · started 2019 · scored riskier than 45% of active trials completed
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT06256484 · started 2024 · scored riskier than 84% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.